imgimg
imgimg
img
img
imgimg
Home
Public Policy Institute
About Public Policy Institute
Research Areas
img
Featured Work
Latest News
Publications Archive
img
Event Highlights
img
Academy of Chinese Studies
Hong Kong Chronicles Institute
Media Centre
About Us
About Our Hong Kong Foundation
img
Benefactors
img
Our Governance
Our Hong Kong Foundation
img
Academy of Chinese Studies
img
Hong Kong Chronicles Institute
img
Advisory Members
img
The Management
Legal and Audit
Annual Reports
Careers
Contact Us
Donate Now
imgimgimgimgimgimgimg
Banner
VIDEO

Professor Chak-sing Lau: Exploring the Opportunities and Future of Clinical Research in Hong Kong

8 Jan 2024 (Mon)

How significant is clinical drug research?

Professor Chak-sing Lau, Dean of LKS Faculty of Medicine at The University of Hong Kong, points out that we can discover new drugs that help patients through clinical drug research. When a drug is put on trial at the patient level, a lot of work has already been done behind the scenes.

Recently, Hong Kong was accepted as an observer of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). "If we can be a member of ICH, we will work with other FDA, EMEA (Europe, Middle East and Africa), and other organisations in the region. This is where the advantage lies," said Professor Lau.

From his point of view, with an organised health care system, Hong Kong has done very well on medical records and drug regulations. In the future, the academic sector needs to prioritize commercialisation of research and cultivate clinical research talents to facilitate Hong Kong becoming a clinical innovation hub.

Click to watch the full interview.

Read the full report at: https://bit.ly/3uW308R


Last Updated 12 Dec 2024 (Thu)

How significant is clinical drug research?

Professor Chak-sing Lau, Dean of LKS Faculty of Medicine at The University of Hong Kong, points out that we can discover new drugs that help patients through clinical drug research. When a drug is put on trial at the patient level, a lot of work has already been done behind the scenes.

Recently, Hong Kong was accepted as an observer of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). "If we can be a member of ICH, we will work with other FDA, EMEA (Europe, Middle East and Africa), and other organisations in the region. This is where the advantage lies," said Professor Lau.

From his point of view, with an organised health care system, Hong Kong has done very well on medical records and drug regulations. In the future, the academic sector needs to prioritize commercialisation of research and cultivate clinical research talents to facilitate Hong Kong becoming a clinical innovation hub.

Click to watch the full interview.

Read the full report at: https://bit.ly/3uW308R

Last Updated 12 Dec 2024 (Thu)
Support Us
Donate Now
Contact us
img
19/F Nan Fung Tower, 88 Connaught Road Central, Hong Kong
img
+852 2603 3001
Follow us on
imgimgimgimg
imgimgimg
ESG Care Organization
© Our Hong Kong Foundation Limited. All Rights Reserved.
Support Us
Donate Now
Contact us
19/F Nan Fung Tower, 88 Connaught Road Central, Hong Kong
Follow us on
imgimgimgimg
imgimgimg
ESG

© Our Hong Kong Foundation Limited. All Rights Reserved.